56.56
price down icon1.27%   -0.73
after-market アフターアワーズ: 56.60 0.04 +0.07%
loading
前日終値:
$57.29
開ける:
$57.28
24時間の取引高:
1.06M
Relative Volume:
0.52
時価総額:
$10.85B
収益:
$2.95B
当期純損益:
$523.88M
株価収益率:
21.03
EPS:
2.69
ネットキャッシュフロー:
$620.18M
1週間 パフォーマンス:
-2.87%
1か月 パフォーマンス:
+2.84%
6か月 パフォーマンス:
-9.55%
1年 パフォーマンス:
-32.74%
1日の値動き範囲:
Value
$56.48
$57.55
1週間の範囲:
Value
$56.48
$59.35
52週間の値動き範囲:
Value
$52.93
$94.85

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
名前
Biomarin Pharmaceutical Inc
Name
セクター
Healthcare (1161)
Name
電話
(415) 506-6700
Name
住所
105 DIGITAL DRIVE, NOVATO, CA
Name
職員
3,040
Name
Twitter
Name
次回の収益日
2024-10-29
Name
最新のSEC提出書
Name
BMRN's Discussions on Twitter

BMRN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
56.56 11.17B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-03 再開されました Morgan Stanley Overweight
2025-02-24 アップグレード Oppenheimer Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-10-30 ダウングレード William Blair Outperform → Mkt Perform
2024-10-10 再開されました Raymond James Outperform
2024-08-20 アップグレード Bernstein Mkt Perform → Outperform
2024-05-17 ダウングレード Robert W. Baird Outperform → Neutral
2024-05-14 開始されました Evercore ISI Outperform
2023-11-15 開始されました Wells Fargo Overweight
2023-10-23 アップグレード Bernstein Underperform → Mkt Perform
2023-09-28 開始されました Raymond James Mkt Perform
2023-09-18 開始されました UBS Buy
2023-07-27 開始されました Scotiabank Sector Perform
2023-07-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-06-14 再開されました Credit Suisse Outperform
2023-03-21 開始されました Bernstein Underperform
2023-02-22 ダウングレード Oppenheimer Outperform → Perform
2023-02-21 開始されました Citigroup Neutral
2023-01-30 開始されました BMO Capital Markets Market Perform
2023-01-18 開始されました Canaccord Genuity Hold
2022-10-31 アップグレード Oppenheimer Perform → Outperform
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-13 再開されました Wedbush Neutral
2022-04-25 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-11-22 アップグレード William Blair Mkt Perform → Outperform
2021-10-07 再開されました Jefferies Buy
2021-09-09 アップグレード Stifel Hold → Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-03-04 再開されました Guggenheim Buy
2021-03-01 アップグレード Evercore ISI In-line → Outperform
2020-08-20 ダウングレード Citigroup Buy → Neutral
2020-08-20 ダウングレード William Blair Outperform → Mkt Perform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-08-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-08-19 ダウングレード Stifel Buy → Hold
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-07-06 繰り返されました Citigroup Buy
2020-01-28 開始されました BMO Capital Markets Market Perform
2020-01-27 開始されました BMO Capital Markets Market Perform
2020-01-24 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-11-27 アップグレード Barclays Equal Weight → Overweight
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-05-23 再開されました Citigroup Buy
2019-04-09 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-12-14 開始されました Wolfe Research Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-07 繰り返されました Stifel Buy
2018-08-03 繰り返されました Stifel Buy
すべてを表示

Biomarin Pharmaceutical Inc (BMRN) 最新ニュース

pulisher
Jul 19, 2025

What analysts say about BioMarin Pharmaceutical Inc. stockTremendous growth potential - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

BioMarin Bets On Growth, But Competition Keeps Pressure On - Finimize

Jul 19, 2025
pulisher
Jul 19, 2025

What drives BioMarin Pharmaceutical Inc. stock priceConsistently superior profits - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

BioMarin Pharmaceutical Inc. Stock Analysis and ForecastUnmatched market performance - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Is BioMarin Pharmaceutical Inc. a good long term investmentDynamic investment growth - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 17, 2025

BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside - Yahoo

Jul 17, 2025
pulisher
Jul 16, 2025

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt? - 富途牛牛

Jul 16, 2025
pulisher
Jul 16, 2025

Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet - Zacks Investment Research

Jul 16, 2025
pulisher
Jul 15, 2025

BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition - Investing.com Nigeria

Jul 15, 2025
pulisher
Jul 14, 2025

What makes BioMarin Pharmaceutical Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru

Jul 14, 2025
pulisher
Jul 14, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - NewsBreak: Local News & Alerts

Jul 14, 2025
pulisher
Jul 13, 2025

BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - MSN

Jul 13, 2025
pulisher
Jul 11, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - MSN

Jul 11, 2025
pulisher
Jul 11, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com

Jul 11, 2025
pulisher
Jul 10, 2025

Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Jul 10, 2025
pulisher
Jul 09, 2025

10 Best Growth Stocks to Buy With Huge Upside Potential - Insider Monkey

Jul 09, 2025
pulisher
Jul 08, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance

Jul 08, 2025
pulisher
Jul 03, 2025

BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment - TipRanks

Jul 03, 2025
pulisher
Jul 03, 2025

BioMarin stock rating initiated at Overweight by Morgan Stanley on Voxzogo growth - Investing.com

Jul 03, 2025
pulisher
Jul 03, 2025

The Top 12 Companies Hiring in Biopharma Now - BioSpace

Jul 03, 2025
pulisher
Jul 02, 2025

The Best Biotech Stocks to Buy - Morningstar

Jul 02, 2025
pulisher
Jul 01, 2025

BioMarin Pharmaceutical completes acquisition of Inozyme Pharma - grafa.com

Jul 01, 2025
pulisher
Jul 01, 2025

BioMarin Pharmaceutical Closes Acquisition of Inozyme Pharma - MarketScreener

Jul 01, 2025
pulisher
Jul 01, 2025

BioMarin Acquires Inozyme for $270M, Gains Late-Stage Enzyme Therapy for Untreated Rare Disease - Stock Titan

Jul 01, 2025
pulisher
Jul 01, 2025

BioMarin completes acquisition of Inozyme Pharma, triggers delisting from Nasdaq - Investing.com

Jul 01, 2025
pulisher
Jun 30, 2025

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 1000 Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A - MSN

Jun 28, 2025
pulisher
Jun 28, 2025

11 Most Undervalued US Stocks According to Analysts - Insider Monkey

Jun 28, 2025
pulisher
Jun 26, 2025

Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies - Reuters

Jun 26, 2025
pulisher
Jun 25, 2025

BioMarin sees long-term strength in Roctavian data - The Pharma Letter

Jun 25, 2025
pulisher
Jun 24, 2025

BioMarin’s hemophilia gene therapy shows sustained results at 5 years - Investing.com

Jun 24, 2025
pulisher
Jun 23, 2025

Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating - Yahoo Finance

Jun 23, 2025
pulisher
Jun 22, 2025

2 Reasons to Watch BMRN and 1 to Stay Cautious - Yahoo Finance

Jun 22, 2025
pulisher
Jun 20, 2025

Inozyme Pharma Halts Annual Meeting as BioMarin Acquisition Nears Completion - Stock Titan

Jun 20, 2025
pulisher
Jun 18, 2025

BioMarin Generates Patient Experience Data With Early And Often Engagement - Clinical Leader

Jun 18, 2025
pulisher
Jun 15, 2025

Jim Cramer on BioMarin: “I Don’t Think It Works Now” - MSN

Jun 15, 2025
pulisher
Jun 14, 2025

BioMarin’s SWOT analysis: stock growth potential amid rare disease focus - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey

Jun 12, 2025
pulisher
Jun 12, 2025

Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com

Jun 12, 2025
pulisher
Jun 12, 2025

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga

Jun 12, 2025
pulisher
Jun 10, 2025

BioMarin Pharmaceutical: Hold Rating Maintained Amid Competitive Pressures and New Data Insights - TipRanks

Jun 10, 2025

Biomarin Pharmaceutical Inc (BMRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
大文字化:     |  ボリューム (24 時間):